2(3H)-噻唑酮,4-(1-甲基乙基)- | 104514-85-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2(3H)-噻唑酮,4-(1-甲基乙基)-
• 英文名称: 4-isopropylthiazole-2(3H)-one
• 英文别名: 2(3H)-Thiazolone, 4-(1-methylethyl)-；4-propan-2-yl-3H-1,3-thiazol-2-one
• CAS: 104514-85-4
• 化学式: C₆H₉NOS
• 分子量: 143.21
• InChiKey: CKYDGOQJQRJZIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-methyl-1,4-dithiocyanatobut-2-ene 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 2(3H)-噻唑酮,4-(1-甲基乙基)-
  参考文献：
  名称：

  通过重排1,4-二硫代氰基丁-2-烯的合成程序

  摘要：

  1,4-二硫代氰基丁-2-烯的热重排可通过1,3-二烯的硫氰化反应或从1,4-二卤代丁-2-烯进行热重排，得到邻位的thiocanatoisothiocyanates，被困以生成噻唑烷酮或二氢噻唑，或间接氨基硫醇。

  DOI：

  10.1039/c39860000576

文献信息

• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Ting Pauline C.

  公开号：US20110224137A1

  公开（公告）日：2011-09-15

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).

  本发明涉及作为二酰基甘油酰基转移酶（“DGAT”）抑制剂的新型杂环化合物，包括所述杂环化合物的药物组合物以及利用这些化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一种示例化合物如下所示：式（I）。
• JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
  申请人：Incyte Corporation

  公开号：US20170087158A1

  公开（公告）日：2017-03-30

  The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.

  本申请涉及Janus激酶（JAK）抑制剂，包括3-环戊基-3- [4-（7H-吡咯[2,3-d]嘧啶-4-基）-1H-吡唑-1-基]丙腈，用于治疗干眼症或改善干眼症的特定症状，如眼部不适，视觉障碍，泪膜不稳定，泪液高渗性和眼表炎症，以及相关的套件和组合物，包括局部组合物。
• MACROCYCLES AS FACTOR XIA INHIBITORS
  申请人：Corte James R.

  公开号：US20120041190A1

  公开（公告）日：2012-02-16

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如此定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆卡利肌酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Zhou Gang

  公开号：US20110319403A1

  公开（公告）日：2011-12-29

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).

  本发明涉及一种新型杂环化合物，作为二酰基甘油酰基转移酶（“DGAT”）抑制剂，制备包含该杂环化合物的制药组合物，并用于治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。该发明的一种示例化合物如下：式（I）。
• BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE
  申请人：Zhou Gang

  公开号：US20120022057A1

  公开（公告）日：2012-01-26

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below (I).

  本发明涉及一种新型杂环化合物，作为二酰基甘油酰基转移酶（“DGAT”）抑制剂，包括该杂环化合物的制药组合物，并且该化合物可用于治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如下所示（I）。